N-acetylcysteine Effects on Tetrahydrocannabinol

Yale University

Status and phase: Terminated; Early Phase 1

Conditions: Healthy

Treatments: Drug: Delta-9-THC; Drug: Placebo; Drug: N-acetylcysteine

Study type: Interventional

Funder types: Other

Identifiers

NCT02335060

1402013406

Details and patient eligibility

About

The overall purpose of this study is to examine the effect of N-acetylcysteine (NAC) on the acute effects of Delta-9-tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with NAC and then assessing their responses to THC.

Enrollment: 5 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Exposed to Cannabis at least once in lifetime

Exclusion criteria

• Cannabis Naive
• Individuals with a documented allergy to N-acetylcysteine

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

5 participants in 4 patient groups, including a placebo group

Active N-acetylcysteine and Active Delta-9-THC

Experimental group

Treatment:

Drug: N-acetylcysteine

Drug: Delta-9-THC

Placebo and Active Delta-9-THC

Placebo Comparator group

Treatment:

Drug: Placebo

Drug: Placebo

Drug: Delta-9-THC

Active N-acetylcysteine and Placebo

Experimental group

Treatment:

Drug: Placebo

Drug: N-acetylcysteine

Drug: Placebo

Placebo and Placebo

Placebo Comparator group

Treatment:

Drug: Placebo

Drug: Placebo